Skip to main content
. 2015 Aug 26;70(11):3080–3086. doi: 10.1093/jac/dkv243

Figure 2.

Figure 2.

Predicted cross-resistance to dolutegravir (twice-daily dosing) in raltegravir recipients with viraemia. DTG, dolutegravir; RAL, raltegravir.